Research programme: neoepitope immunotherapies - Immunovaccine

Drug Profile

Research programme: neoepitope immunotherapies - Immunovaccine

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunovaccine
  • Developer Immunovaccine; University of Connecticut
  • Class Cancer vaccines; Immunotherapies; Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Jul 2017 Immunovaccine files for patent protection for Depovax-based rapid formulation process in Canada
  • 03 Nov 2016 Preclinical trials in Cancer in USA (Parenteral)
  • 05 May 2016 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top